0001104659-21-149433.txt : 20211214 0001104659-21-149433.hdr.sgml : 20211214 20211214092032 ACCESSION NUMBER: 0001104659-21-149433 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211214 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211214 DATE AS OF CHANGE: 20211214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKWELL MEDICAL, INC. CENTRAL INDEX KEY: 0001041024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383317208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23661 FILM NUMBER: 211489829 BUSINESS ADDRESS: STREET 1: 30142 WIXOM ROAD CITY: WIXOM STATE: MI ZIP: 48393 BUSINESS PHONE: 8004493353 MAIL ADDRESS: STREET 1: 30142 WIXOM ROAD CITY: WIXOM STATE: MI ZIP: 48393 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20120530 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL, INC. DATE OF NAME CHANGE: 20120525 FORMER COMPANY: FORMER CONFORMED NAME: ROCKWELL MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 19970722 8-K 1 tm2135375d1_8k.htm FORM 8-K
0001041024 false 0001041024 2021-12-14 2021-12-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):  December 14, 2021

 

ROCKWELL MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 000-23661 38-3317208
(State or other jurisdiction
of incorporation)		 (Commission File Number) (IRS Employer
Identification No.)

 

30142 S. Wixom Avenue, Wixom, Michigan 48393

(Address of principal executive offices, including zip code)

 

(248) 960-9009

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class  Trading Symbol  Name of Each exchange on which registered
Common Stock, par value $0.0001  RMTI  Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01        Other Events.

 

On December 14, 2021, Rockwell Medical, Inc. (the “Company”) issued a press release regarding the Company’s receipt of a request from the U.S. Food and Drug Administration for additional data supporting its Investigational New Drug application for its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01        Financial Statements and Exhibits.

 

(d) Exhibits        The following exhibit is being furnished herewith:

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press Release, dated December 14, 2021
104   Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ROCKWELL MEDICAL, INC.
     
Date: December 14, 2021 By:  /s/ Russell Ellison
    Russell Ellison
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2135375d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

 

WIXOM, Mich., December 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

 

“We are breaking new ground with this study, which is the first of its kind, evaluating the use of parenteral iron in treating iron deficiency anemia in the rapidly-growing home infusion setting. The study proposal includes a novel dosing regimen, one that is fine-tuned to match the preferences of caregivers and patients receiving health care at home. We are working closely with FDA to ensure that our planned approach is well suited for this patient population,” said Russell Ellison, M.D., President and Chief Executive Officer of Rockwell Medical.

 

FDA requested that additional data related to the microbiology and short-term stability of FPC be submitted to further support the drug administration method proposed for the study. The company expects to run these additional studies, complete the required analysis, and provide the requested data in the first half of 2022. “We have a clear understanding of the request from FDA, and we believe there is a well-defined path forward to generate the data. The effort will help us refine our study approach, which is carefully designed for the home infusion application. We expect that these activities will have a minimal impact on the timing of our planned dosing of the first patient in this study,” said Marc Hoffman, M.D., Chief Medical Officer of Rockwell Medical.

 

“This important feedback from FDA strengthens our confidence in the potential value of this therapy. We are working to ensure that this product is studied with the patient and caregiver preferences in mind. The ultimate success of our project would mean patients will have access to a treatment for iron deficiency anemia in the home, so they could potentially avoid visits to an office or clinic to receive iron. We believe this may be a significant advance in the care of chronically ill patients with iron deficiency anemia who wish to avoid visits to healthcare facilities and the associated risks,” said Dr. Ellison.

 

Once the additional data is submitted, Rockwell must wait 30 calendar days before treating any patients in the clinical trial. During this time, FDA has an opportunity to review the IND and the additional data that is submitted.

 

 

 

 

 

 

About Rockwell Medical

 

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

 

Rockwell Medical Forward-Looking Statements

 

Certain statements in this press release, including without limitation statements relating to the timing of completion of response activities, the impact of the response activities on the timing of dosing the first patient in the trial and the path forward to resolve the FDA’s questions, may constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as, “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “could,” “can,” “would,” “develop,” “plan,” “potential,” “predict,” “forecast,” “project,” “intend” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical’s SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: Rockwell’s ability to timely lift the clinical hold for the planned home infusion trial, the impact of the COVID-19 pandemic on Rockwell’s business, including any clinical trials, and the FDA’s response time, the risks of current treatment patterns in the home infusion setting for iron deficiency anemia and whether the FDA will raise any additional issues with the IND during its review period; and those risks more fully discussed in the “Risk Factors” section of our Quarterly Report on Form 10-Q for the period ended September 30, 2021 and of our Annual Report on Form 10-K for the year ended December 31, 2020, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

 

###

 

 

 

 

 

 

ROCKWELL MEDICAL CONTACTS

 

Investors:

Argot Partners

212.600.1902

Rockwell@argotpartners.com

 

Media:

David Rosen

Argot Partners

212.600.1902

david.rosen@argotpartners.com

 

 

 

 EX-101.SCH 3 rmti-20211214.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rmti-20211214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 rmti-20211214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2135375d1_ex99-1img001.jpg GRAPHIC begin 644 tm2135375d1_ex99-1img001.jpg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end XML 7 tm2135375d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001041024 2021-12-14 2021-12-14 iso4217:USD shares iso4217:USD shares 0001041024 false 8-K 2021-12-14 ROCKWELL MEDICAL, INC. DE 000-23661 38-3317208 30142 S. Wixom Avenue Wixom, Michigan MI 48393 248 960-9009 false false false false Common Stock, par value $0.0001 RMTI NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Dec. 14, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 14, 2021
Entity File Number 000-23661
Entity Registrant Name ROCKWELL MEDICAL, INC.
Entity Central Index Key 0001041024
Entity Tax Identification Number 38-3317208
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 30142 S. Wixom Avenue
Entity Address, City or Town Wixom, Michigan
Entity Address, State or Province MI
Entity Address, Postal Zip Code 48393
City Area Code 248
Local Phone Number 960-9009
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol RMTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rockwellmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2135375d1_8k.htm rmti-20211214.xsd rmti-20211214_lab.xml rmti-20211214_pre.xml tm2135375d1_ex99-1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2135375d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2135375d1_8k.htm" ] }, "labelLink": { "local": [ "rmti-20211214_lab.xml" ] }, "presentationLink": { "local": [ "rmti-20211214_pre.xml" ] }, "schema": { "local": [ "rmti-20211214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rmti", "nsuri": "http://rockwellmed.com/20211214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135375d1_8k.htm", "contextRef": "From2021-12-14to2021-12-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://rockwellmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135375d1_8k.htm", "contextRef": "From2021-12-14to2021-12-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://rockwellmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-149433-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-149433-xbrl.zip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end